NDC 67296-2324-03 - Jardiance
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 67296-2324
- Requested NDC
- 67296-2324-03
- Package NDCs from labels
- 67296-2324-3, 67296-2324-03
- Manufacturer
- Redpharm Drug
- Effective date
- 2026-08-26
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Jardiance - Redpharm Drug | Redpharm Drug | 2026-08-26 | HUMAN PRESCRIPTION DRUG LABEL |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Jardiance | EMPAGLIFLOZIN | Redpharm Drug | 59ed43d9-b4e0-72a2-e063-6394a90a327d | 2026-08-26 | Warnings, Adverse reactions | NDA204629 67296-2324-3 67296-2324 67296232403 1545666 1545668 59ed43d9-b4e1-72a2-e063-6394a90a327d 59ed43d9-b4e0-72a2-e063-6394a90a327d HDC1R2M35U |
| Synjardy | EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | Boehringer Ingelheim Pharmaceuticals, Inc. | 0fdd0255-0055-65f3-b2c0-db8fbb87beae | 2026-08-25 | Boxed warning, Warnings, Adverse reactions | HDC1R2M35U |
| Trijardy XR | EMPAGLIFLOZIN, LINAGLIPTIN, METFORMIN HYDROCHLORIDE | Boehringer Ingelheim Pharmaceuticals, Inc. | 71873567-9594-452a-bb92-34a129adecac | 2026-08-24 | Boxed warning, Warnings, Adverse reactions | HDC1R2M35U |
| Synjardy XR | EMPAGLIFLOZIN, METFORMIN HYDROCHLORIDE | Boehringer Ingelheim Pharmaceuticals, Inc. | 8006ba29-ee3a-f852-a9bb-c8ec9b41cf66 | 2026-08-11 | Boxed warning, Warnings, Adverse reactions | HDC1R2M35U |
| Jardiance | EMPAGLIFLOZIN | Aphena Pharma Solutions - Tennessee, LLC | 334f1b3d-5670-6685-e063-6294a90a7e47 | 2026-06-17 | Warnings, Adverse reactions | NDA204629 1545664 1545658 HDC1R2M35U |
| Jardiance | EMPAGLIFLOZIN | Cardinal Health 107, LLC | 5777b8a8-ada6-4950-8548-43a1de11f075 | 2026-02-17 | Warnings, Adverse reactions | NDA204629 1545666 1545668 1545664 1545658 HDC1R2M35U |
| Jardiance | EMPAGLIFLOZIN | Boehringer Ingelheim Pharmaceuticals, Inc. | faf3dd6a-9cd0-39c2-0d2e-232cb3f67565 | 2026-01-30 | Warnings, Adverse reactions | NDA204629 0597-0153 1545666 1545668 1545664 1545658 09daa78d-f417-436c-a29e-029c015ca6d6 faf3dd6a-9cd0-39c2-0d2e-232cb3f67565 HDC1R2M35U |
| Glyxambi | EMPAGLIFLOZIN AND LINAGLIPTIN | Boehringer Ingelheim Pharmaceuticals, Inc. | ddbab689-f76c-488c-9613-4168d41dd730 | 2026-01-20 | Warnings, Adverse reactions | HDC1R2M35U |
| Jardiance | EMPAGLIFLOZIN | Aphena Pharma Solutions - Tennessee, LLC | 8b6261f6-4bdc-462e-8af1-4064664c62f3 | 2025-10-27 | Warnings, Adverse reactions | NDA204629 1545666 1545668 HDC1R2M35U |
| Jardiance | EMPAGLIFLOZIN | A-S Medication Solutions | a77214ca-572e-485e-aae9-f7950187e5fb | 2023-08-08 | Warnings, Adverse reactions | NDA204629 1545666 1545668 HDC1R2M35U |
| JARDIANCE | EMPAGLIFLOZIN | A-S Medication Solutions | 942a82a4-cbbd-4e44-9965-8d03f767912b | 2023-07-24 | Warnings, Adverse reactions | NDA204629 1545664 1545658 HDC1R2M35U |
| JARDIANCE | EMPAGLIFLOZIN | A-S Medication Solutions | 1782b947-4a72-4feb-a488-1469d9af82bd | 2023-05-03 | Warnings, Adverse reactions | NDA204629 1545664 1545658 HDC1R2M35U |
| JARDIANCE | EMPAGLIFLOZIN | A-S Medication Solutions | f2b41c77-0abb-40ee-8578-86a748d0e19e | 2023-05-03 | Warnings, Adverse reactions | NDA204629 1545666 1545668 HDC1R2M35U |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.